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Abstract
Background: Rare cancers comprise almost a quarter of all cancers in Europe, and patients generally have poorer
outcomes than those suffering from more common cancers. This is attributed in part to a general lack of
knowledge and awareness of rare cancers. This review aims to examine the communication strategies being used
throughout the world to inform on rare cancers and to highlight any opportunities for improvement.
Methods: A systematic review of literature published in English prior to November 2018 will be conducted,
screening articles from the electronic databases MEDLINE, PubMed, EMBASE, Web of Science, PsycINFO, CINAHL
Plus and the Cochrane Database of Systematic Reviews. Grey literature databases (GreyLit, OpenGrey) will also be
searched in order to screen for any unpublished works. As well as primary literature, reference lists will be examined
via forward and reverse citation screening. The review will be reported using the Preferred Reporting Items for
Systematic Reviews and Meta-Analysis (PRISMA). Titles and abstracts will first be examined for eligibility, with
remaining studies undergoing a full-text screening before being included in the final review. Individual studies will
be screened for bias, and a meta-analysis performed provided there is enough data. If insufficient homogenous
literature exists, a narrative summary of the literature will be produced.
Discussion: Despite the broad topic and width of study type that will be considered, this review hopes to provide
a reflective summary of the communication strategies available for people living with and working with rare cancer.
It aims to reveal any gaps in the resources available, to contribute to the long-term improvement of diagnosis and
management of rare cancers.
Systematic review registration: PROSPERO CRD42018099784
Keywords: Rare Cancer, Communication, Strategies, Information, Healthcare professional, Carers, Patients
Background
The definition of rare cancer varies throughout the world.
In Europe, a cancer is described as “rare” if it has an inci-
dence of less than 6 per 100,000 diagnosed people per year
[1], whilst in the USA, the threshold is 15 new diagnoses
per 100,000 per year [2]. Consequently, some cancers
which are considered “rare” in one country/region may be
considered “common” in another. For example, under the
European Union, Surveillance of Rare Cancer in Europe
(RARECARE) definition, cancers such as adenocarcinoma
(with variants) of the colon/rectum/pancreas/lung/corpus
uteri/ovary/prostate, renal cell carcinoma (with variants)
and haematological malignancies such as multiple mye-
loma/plasmacytoma (and heavy chain disease) and diffuse
B cell lymphoma are classified as rare in Europe but are
considered common in the USA [3, 4].
Despite the name, rare cancers collectively account for
around 24% of all cancer diagnoses in Europe [3], and
20% of those in the USA [4]. One reason why the fre-
quency of cancer diagnoses is thought to be increasing is
due to the introduction of molecular techniques, com-
bining with previously used histological techniques, to
diagnose and classify cancer types. Such techniques have
caused cancer types that were previously classified as
“common” to instead be seen as a larger group of mo-
lecularly distinct rare cancers [5].
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Although rare cancers as a whole constitute a signifi-
cant health concern to the general public, the scarcity of
patients with an individual rare cancer type within de-
fined geographic areas makes it very difficult to produce
clinical trial data that is statistically reliable [6]. Patients
suffering from rare cancers experience significantly
poorer outcomes than patients suffering from more
common cancers, with the average 5-year survival for
rare cancers being up to 20% lower than that of a com-
mon cancer [4]. International collaborations have proved
beneficial, particularly for the research of extremely rare
cancers, but funding is difficult to obtain and little work
has been done to identify treatment options or to im-
prove understanding of rare cancer development [6].
Another contributor to the poorer outcomes in pa-
tients with rare cancers is the time to diagnosis. Patients
with rare cancers tend to be diagnosed at a later stage
and are often initially misdiagnosed with a more com-
mon cancer [7]. Delayed diagnosis is detrimental to pa-
tient prognosis. Alongside a shortage of sufficient
specialised facilities, this delay in diagnosis is partly due
to a lack of awareness and knowledge of rare cancers by
health professionals [8] and patients alike, which reflects
a wider gap in the understanding of these diseases
throughout the general population. This has a negative
impact on communication and understanding for all af-
fected by rare cancers. For example, a study carried out
in England reported 43.3% of myeloma patients waited
more than 3months to present to their general practi-
tioner. A third of all patients included in the study (in-
cluding myeloma, leukaemia and lymphoma patients)
said they were not aware that their symptoms were ser-
ious [9]. Social media has revolutionised healthcare,
allowing efficient communication and exchange of infor-
mation between health professionals and the general
public [10]. However, the implications for communica-
tion surrounding rare cancers have not been examined.
Review aim and objectives
This review aims to examine the current literature sur-
rounding communication of information on rare cancers
by:
1. Comprehensively identifying and evaluating
publications pertaining to strategies for rare cancer
information communication
2. Providing a synthesis of the types of strategies
available and their global accessibility
3. Highlighting who these strategies are targeted for
(patients, carers, healthcare professionals, the
general public) and the perceptions/understanding
of the communication intervention by these groups
where available.
Rationale for review
Rare cancers collectively account for more cases of can-
cer than any individual type [11] and therefore represent
an important health problem. A general lack of know-
ledge contributes to the high proportion of misdiagnosis,
amongst other factors [12]. This review aims to shed
light on the communication strategies available to aid
understanding of rare cancers, with the hope of
highlighting possible avenues for improvement in the in-
formation available. In the long term, this could lead to
a general increase in the awareness and knowledge of
rare cancers and hopefully improve on early diagnosis
and minimise misdiagnoses by shortening the diagnostic
pathway. Increased communication and understanding
could also improve management by carers and health-
care professionals, thereby improving outcomes, such as
long-term survival, for those affected by rare cancer.
Methods
This protocol was created using guidance stated on the
BMC website [13] and using the Preferred Reporting
Items for Systematic Review and Meta-Analysis Proto-
cols (PRISMA-P) checklist (see Additional file 1). This
protocol has been registered on the PROSPERO data-
base of prospectively registered systematic reviews (Ref-
erence: CRD42018099784).
Inclusion criteria
The inclusion criteria were designed in reference to the
Population, Intervention, Comparison, Outcome (PICO)
framework [14], although certain aspects of this frame-
work are not completely applicable to the topic of the
review.
Study population
Only studies involving human participants will be con-
sidered. There is no age restriction for human
participants.
Intervention
The interventions highlighted in this review will include
a range of communication strategies used to convey in-
formation about rare cancers (for example treatment,
diagnosis and general awareness). The rare cancer de-
scribed in each study must meet the criteria for a rare
disease in their place of research, e.g. the European or
American definition of a rare cancer.
Comparator
Where applicable, this review will compare studies of
rare cancer within a single group of participants, pre-
and post-implementation of a communication interven-
tion strategy. Studies which meet the population,
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intervention and outcome elements of our eligibility cri-
teria but not this comparator will still be included.
Outcome(s)
Data on the range of communication strategies that have
been used when informing on rare cancers will be
examined.
By examining the origin of publication, this review will
also examine the accessibility of different communica-
tion strategies that are available globally.
If available, information on how well the intended
audience understood the information provided using the
communication strategies will be considered; however,
due to the limited literature in the area, it is predicted
that information regarding patient understanding may
not be available.
Types of study to be included
There is no restriction on the type of study eligible for
this review.
Time frame
All literature published in November 2018 and prior are
eligible. There is no restriction on the time frame of
studies that will be considered, to encapsulate as many
relevant studies as possible.
Context
Publications from any country of origin are eligible. Pub-
lications must be written in English.
Information sources
Several bibliographic databases will be searched for rele-
vant material for inclusion in the review. Such databases
include MEDLINE, PubMed, EMBASE, Web of Science,
PsycINFO, CINAHL and the Cochrane Database of Sys-
tematic Reviews. Grey Literature databases GreyLit and
OpenGrey will also be searched. As well as screening
primary publications, forward and reverse citation
screening will also be undertaken.
A search strategy will be created and adapted to each
database. Search terms will be developed from several
sources, including ‘RareCareNet’ [15], ‘Cancer Caring
Coping’ [16], ‘Rare Cancers Europe’ [17] and similar or-
ganisations worldwide. The terms will include keywords
relevant to communication and delivery of information,
different forms of communication strategies and phrases
related to the intended audience, whether it be patients,
carers or healthcare professionals.
Search strategy
A draft of the search strategies to be used for MEDLINE
and other databases is attached (see Additional file 2).
Study records
Data management
Data will be managed using online reference manage-
ment tools such as EndNote. These will also be used to
record reasons for exclusion in each case.
Selection and data collection process
Initial search results from all databases will be screened
for duplicates. Titles and abstracts will then be screened
and excluded if they are not considered relevant to the
review topic. Finally, full text will be screened to confirm
eligibility of the publication. A summary of the selection
process will be made into a flow diagram following the
PRISMA design [18].
Two independent reviewers (CB and KK) will conduct
the search, examine data and ensure papers meet the in-
clusion criteria mentioned previously, with any disagree-
ments to be resolved by discussion. If a consensus
cannot be reached, a third independent individual (KM)
will make the final decision. Data will be extracted, in
duplicate, by two or more independent reviewers and
collected into a table such as that of Table 1. This table
will be checked and should there be any disagreements,
these will be discussed with a third co-author (HMcA)
who will make the decision if consensus cannot be
reached. If additional or further information other than
that contained in the publication is required, attempts to
contact the original authors will be made.
Quality assessment
Studies will be critically appraised to assess methodo-
logical quality using the appropriate checklists for the
study design, available from the Joanna Briggs Institute
[19] and the Critical Appraisal Skills Programme (CASP)
[20]. As these tools do not provide a quantitative score,
studies will be assigned as having either weak, moderate
or strong methodological rigour.
Data synthesis
If there are three or more publications investigating the
same area with the same outcomes, a meta-analysis shall
be performed. However, due to the scarce nature of lit-
erature surrounding rare cancer, as well as the
wide-ranging nature of communication strategies, it is
expected that there will be insufficient data available for
a meta-analysis.
Dependent on the number of studies to meet the in-
clusion criteria, a narrative synthesis or, more likely, a
descriptive summary will be the most suitable way to
present the findings from this review [21]. However,
should the bodies of literature be heterogeneous,
where the same problem has been conceptualised and
investigated in different ways, then a meta-narrative ap-
proach to the synthesis will be contemplated [22, 23]. As
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such, each publication will be examined and information
such as the following items extracted and considered:
i) Type of communication strategy employed
ii) Response to strategy
iii) Place of publication
iv) Date of publication
By doing this, any particularly widely used communi-
cation strategy will be identified, as well as any short-
comings in data availability. These will identify any
discrepancies in accessibility to communication strat-
egies and information. It will also be possible to observe
if there is particular focus on certain rare cancer types
over others. By looking at the date of publication, it will
be possible to observe whether the number of studies on
communication in rare cancer is increasing over time, as
more and more rare cancers are discovered.
Discussion
A significant proportion of all cancers are considered
rare cancers. Despite this, there has been comparatively
little research into the area. This review aims to look at
the communication strategies in place for providing in-
formation about rare cancer, particularly as the import-
ance of the internet and social media in healthcare
become more apparent. For instance, the work by Pem-
maraju and colleagues considers the creation and use of
disease-specific hashtags on Twitter, for example
#MPNSM (myeloproliferative neoplasms on social
media), for the dissemination of information and facili-
tated interaction of healthcare stakeholders all over the
world in the field of myeloproliferative neoplasms [24].
Other aspects of communication are reflected in the
work of Peate which emphases the importance of effect-
ive health education in the case of testicular cancer,
which although a rare cancer is the commonest malig-
nancy in the UK among men aged 20–34 years and is
the most curable [25]. The benefit of consortiums and
collaborations in diagnosis and survivorship of rare can-
cers is considered by Blay and colleagues [26]. Addition-
ally, there is the benefit of the provision of information
to patients with rare cancers such that they can make in-
formed decisions, as reported by Schultz, in the case of
addressing the needs of patients with medullary thyroid
carcinoma through the use of internet discussion forums
[27]. These are just some of the communications strat-
egies envisaged to be robustly reported on from the
completed protocol.
Due to the scarcity of rare cancer literature as a whole,
it is expected that there will be relatively few publica-
tions examining such communication strategies directly.
Therefore, this review has designed a thorough search
strategy that will encapsulate as many relevant
publications as possible, such as additional inclusion of
studies in which communication and rare cancer is not
the primary focus. For example, we would include a
study that examined how patients were informed as part
of a larger investigation looking at a specific intervention
for a specific rare cancer type, as well as studies which
focus on communication and rare cancer only.
This broad approach aims to ensure that the resulting
review is able to compare several studies and encapsu-
late all the ways in which information about rare cancer
is communicated. As such, the studies included are un-
likely to have homogenous interventions and outcomes,
meaning a narrative synthesis of the data extracted will
likely be more feasible than the preferable meta-analysis.
In order to identify English-based communication re-
sources that can be easily adapted to the UK setting,
only studies published in English will be eligible for in-
clusion. Whilst it is expected that some important
non-English-language studies may be missed by this ap-
proach, a comprehensive search strategy that includes
grey literature searches will be employed to ensure that
all relevant English language studies are identified.
Despite the challenges this review faces in analysing
literature in a developing field of research, the data dis-
covered will be valuable in identifying areas of commu-
nication in rare cancer which need improvement. This
information could inform healthcare professionals,
carers and patients alike, leading to a raised awareness
which could have many beneficial outcomes, including
shortening the diagnostic pathway and improving the
prognosis for those suffering from a rare cancer [28].
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